🔥A post hoc analysis of SELECT-SWITCH from EULAR 2026: A JAKi vs second TNFi in patients with RA stratified by primary or secondary nonresponse or intolerance to a first TNFi. See the poster: https://t.co/Q5zndXJ2R3 Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/CWZARhA8S5

The Power of Self-Management with Chronic Low Back Pain Almost everyone will deal with back pain at some point in their lives. Most recover quickly — but for about 20% of people, acute pain becomes a chronic condition that interferes with daily life and keeps them out of the https://t.co/urZPsVwCV8

Uric Acid: Is Lower Better? There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs? https://t.co/yVZOuMhZmr https://t.co/Ldc1pBQThH

< 40% of gout patients are on ULT; <40% of ULT-treated gout patients achieve T2T (SUA < 6.0 mg/dl). For more gout content, follow our Gout: More than Flares campaign at https://t.co/j3iLMZz4HM, https://t.co/zFTozS62me

How should imaging guide the diagnosis and management of gout? Hear from Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi, moderated by Dr. Jack Cush, as they discuss ultrasound, DECT, crystal identification, and more. 📅 Reserve your seat today. Link: https://t.co/GySPzyVc1b

Gout is more than an episodic arthritis, it's a systemic inflammatory disease. Watch Dr. Robert Terkeltaub discuss 3 New Things it Pays to Know About Gout Pathobiology, including emerging insights that are shaping how we understand and manage gout. Watch now on RheumNow: https://t.co/nri3WDz7kS

The global Chronic Refractory Gout Market is projected to grow from ~$2.94 billion USD in 2022 to nearly $10.07 billion USD by 2036, reflecting introduction of innovative therapies. Chronic Refractory Gout in the 7Major Markets exceeded 400,000 pts in 2025 (>200K in USA) https://t.co/MSzBNTXTPj

ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial https://t.co/ax0zwNcxYX

New research shows synovial lining enriched in macrophages expressing SPP1 (encoding osteopontin) in proximity to fibroblasts and fibrin deposits. SPP1+ macrophages degrade fibrin & promote fibroblast proliferation that deposit collagen & does the damage, joint remodeling. A new https://t.co/hrJoQXpAH8

Whats the BEST FIRST Rx in DMARD-Naive #RA - Tofacitinib or MTX. RCTs (ORAL Start, RA-BEGIN, SELECT-EARLY, FINCH 3) prove JAKi > MTX. A recent 116 RCT from China also shows Tofa > MTX by SDAI50 (94% v 75%) @3 mos & Tofa was more cost effective. https://t.co/KL2qlDgF6D https://t.co/wNVBgQkaMI

EULAR26: ANCHOR-RA Study of RA-ILD People with rheumatoid arthritis are at risk of developing interstitial lung disease (RA-ILD), which is associated with high mortality. ANCHOR-RA is a large, international cross-sectional prospective study that will enable the development of a https://t.co/tsOpA4SAZP